Prenatal Diagnosis of Vasa Previa: Outpatient versus Inpatient Management

Abstract

Objective The aim of this study was to compare the pregnancy outcome of two different management strategies: outpatient versus inpatient in women with prenatal diagnosis of vasa previa.

Materials and Methods This is a retrospective cohort study conducted at a single tertiary center. Women with a prenatally diagnosed vasa previa between January 2007 and June 2017 were included. Obstetric and neonatal outcomes were compared between two management strategies: elective admission at 34 weeks of gestation or outpatient management unless there were signs of labor or premature contractions.

Results A total of 109 women met the inclusion criteria: 75 (68.8%) women in the inpatient group and 34 (31.2%) in the outpatient group. Women in the inpatient group were more likely to receive antenatal steroids (57.3 vs. 26.4%, p = 0.002) and were less likely to have an urgent cesarean section (34.6 vs. 58.8%, respectively, p < 0.001) compared with outpatient group. There was no difference in the rate of neonatal complications (inpatient: 64.6% vs. outpatient: 52.7%, p = 0.27) or neonatal anemia requiring transfusion (2.7 vs. 5.8%, respectively, p = 0.5) between the groups.

Conclusion The rate of elective cesarean section and exposure to antenatal steroids was higher in patients with vasa previa who were admitted electively at 34 weeks of gestation compared with patients who were managed as outpatient.

Keywords

vasa previa - prenatal diagnosis - management - elective cesarean section - late preterm

• Reference

• 1 Silver RM. Abnormal placentation: placenta previa, vasa previa, and placenta accreta. Obstet Gynecol 2015; 126 (03) 654-668
• 2 Gandhi M, Cleary-Goldman J, Ferrara L, Ciorica D, Saltzman D, Rebarber A. The association between vasa previa, multiple gestations, and assisted reproductive technology. Am J Perinatol 2008; 25 (09) 587-589
• 3 Hasegawa J, Matsuoka R, Ichizuka K, Fujikawa H, Sekizawa A, Okai T. Umbilical cord insertion to the lower uterine segment is a risk factor for vasa previa. Fetal Diagn Ther 2007; 22 (05) 358-360
• 4 Oyelese Y, Catanzarite V, Prefumo F. , et al. Vasa previa: the impact of prenatal diagnosis on outcomes. Obstet Gynecol 2004; 103 (5 Pt 1): 937-942
• 5 Ruiter L, Kok N, Limpens J. , et al. Systematic review of accuracy of ultrasound in the diagnosis of vasa previa. Ultrasound Obstet Gynecol 2015; 45 (05) 516-522
• 6 Vintzileos AM, Ananth CV, Smulian JC. Using ultrasound in the clinical management of placental implantation abnormalities. Am J Obstet Gynecol 2015; 213 (4, Suppl): S70-S77
• 7 Baulies S, Maiz N, Muñoz A, Torrents M, Echevarría M, Serra B. Prenatal ultrasound diagnosis of vasa praevia and analysis of risk factors. Prenat Diagn 2007; 27 (07) 595-599
• 8 Oyelese Y, Chavez MR, Yeo L. , et al. Three-dimensional sonographic diagnosis of vasa previa. Ultrasound Obstet Gynecol 2004; 24 (02) 211-215
• 9 American College of Obstetricians and Gynecologists' Committee on Obstetric Practice; Society for Maternal–Fetal Medicine. Committee Opinion No.677: antenatal corticosteroid therapy for fetal maturation. Obstet Gynecol 2016; 128 (04) e187-e194
• 10 Crowther CA, McKinlay CJ, Middleton P, Harding JE. Repeat doses of prenatal corticosteroids for women at risk of preterm birth for improving neonatal health outcomes. Cochrane Database Syst Rev 2015; (07) CD003935
• 11 Garite TJ, Kurtzman J, Maurel K, Clark R. . Obstetrix Collaborative Research Network. Impact of a ‘rescue course’ of antenatal corticosteroids: a multicenter randomized placebo-controlled trial. Am J Obstet Gynecol 2009; 200 (03) 248.e1-248.e9
• 12 Kulkarni A, Powel J, Aziz M. , et al. Vasa previa: prenatal diagnosis and outcomes: thirty-five cases from a single maternal-fetal medicine practice. J Ultrasound Med 2018; 37 (04) 1017-1024
• 13 Nohuz E, Boulay E, Gallot D, Lemery D, Vendittelli F. Can we perform a prenatal diagnosis of vasa previa to improve its obstetrical and neonatal outcomes?. J Gynecol Obstet Hum Reprod 2017; 46 (04) 373-377
• 14 Melcer Y, Jauniaux E, Maymon S. , et al. Impact of targeted scanning protocols on perinatal outcomes in pregnancies at risk of placenta accreta spectrum or vasa previa. Am J Obstet Gynecol 2018; 218 (04) 443.e1-443.e8
• 15 Catanzarite V, Cousins L, Daneshmand S. , et al. Prenatally diagnosed vasa previa: a single-institution series of 96 cases. Obstet Gynecol 2016; 128 (05) 1153-1161
• 16 Gagnon R. No. 231-guidelines for the management of vasa previa. J Obstet Gynaecol Can 2017; 39 (10) e415-e421
• 17 Hasegawa J, Arakaki T, Ichizuka K, Sekizawa A. Management of vasa previa during pregnancy. J Perinat Med 2015; 43 (06) 783-784
• 18 Sinkey RG, Odibo AO, Dashe JS. ; Society of Maternal-Fetal (SMFM) Publications Committee. #37: Diagnosis and management of vasa previa. Am J Obstet Gynecol 2015; 213 (05) 615-619
• 19 Sullivan EA, Javid N, Duncombe G. , et al. Vasa previa diagnosis, clinical practice, and outcomes in Australia. Obstet Gynecol 2017; 130 (03) 591-598
• 20 Vahanian SA, Lavery JA, Ananth CV, Vintzileos A. Placental implantation abnormalities and risk of preterm delivery: a systematic review and metaanalysis. Am J Obstet Gynecol 2015; 213 (4, Suppl): S78-S90
• 21 Robinson BK, Grobman WA. Effectiveness of timing strategies for delivery of individuals with vasa previa. Obstet Gynecol 2011; 117 (03) 542-549
• 22 Swank ML, Garite TJ, Maurel K. , et al; Obstetrix Collaborative Research Network. Vasa previa: diagnosis and management. Am J Obstet Gynecol 2016; 215 (02) 223.e1-223.e6
• 23 Gyamfi-Bannerman C. ; Society for Maternal-Fetal Medicine (SMFM). Electronic address: [e-mail]. Society for Maternal-Fetal Medicine (SMFM) Consult Series #44: Management of bleeding in the late preterm period. Am J Obstet Gynecol 2018; 218 (01) B2-B8
• 24 Engle WA, Tomashek KM, Wallman C. ; Committee on Fetus and Newborn, American Academy of Pediatrics. “Late-preterm” infants: a population at risk. Pediatrics 2007; 120 (06) 1390-1401